Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Usi

Journal Article · · J. Med. Chem.

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
DOE - Office Of Science; INDUSTRY
OSTI ID:
1834907
Journal Information:
J. Med. Chem., Vol. 64, Issue (19)
Country of Publication:
United States
Language:
ENGLISH

References (31)

Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches January 2017
Bromodomain: an acetyl-lysine binding domain January 2002
The bromodomain interaction module May 2012
Functions of Site-Specific Histone Acetylation and Deacetylation June 2007
Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions September 2012
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers April 2013
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc September 2011
Targeting MYC dependence in cancer by inhibiting BET bromodomains September 2011
Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression August 2015
Selective inhibition of BET bromodomains September 2010
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia August 2011
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia October 2011
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer September 2013
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins November 2012
Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma February 2013
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. November 2013
Suppression of inflammation by a synthetic histone mimic November 2010
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells May 2015
Achieving clinical success with BET inhibitors as anti-cancer agents March 2021
BET inhibitor resistance emerges from leukaemia stem cells September 2015
Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds April 2012
Abstract 5789: Discovery of clinical candidate BMS-986158, an oral BET inhibitor, for the treatment of cancer July 2018
Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters November 2003
Beamline 08ID-1, the prime beamline of the Canadian Macromolecular Crystallography Facility June 2011
Integration, scaling, space-group assignment and post-refinement January 2010
Scaling and assessment of data quality December 2005
[20] Processing of X-ray diffraction data collected in oscillation mode January 1997
Phaser crystallographic software July 2007
Refinement of severely incomplete structures with maximum likelihood in BUSTER–TNT November 2004
Features and development of Coot March 2010
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments March 2013